A multicenter study to compare the antidepressant efficacy and the tolerance of moclobemide (Ro 11-1163) to clomipramine was performed in parallel groups of patients with minor depression. The duration of the study was 6 weeks, with weekly assessments by means of Hamilton Scale of Depression (HRDS) and the Clinical Global Impression (CGI). The efficacy of moclobemide was found to be as good as that of clomipramine. The results for tolerability were possibly in favor of moclobemide. It was recommended that consumption of tyramine-containing foods be kept to a minimum or avoided and no hypertensive crises were reported
A double-blind, randomized trial is described which was designed to compare the clinical effect of 1...
Objective: To review the efficacy and safety of moclobemide in comparison with TCAs (for our purpose...
The aim of this prospectively randomized, double-blind, parallel group, multicentre study was to com...
Moclobemide was compared with placebo for antidepressant activity, tolerance and safety in 2 paralle...
Moclobemide was compared to placebo in two parallel groups of depressed patients, in a multicenter r...
A dissertation submitted to Faculty of Medicine in part fulfilment of the required for the degree ...
An international, multicenter, placebo-controlled study was undertaken to determine the safety and a...
This paper reports the results of a multicentre study of the new monoamine oxidase inhibitor, moclob...
Thirty-two patients with primary depression completed treatment either with mianserin (30 to 60 mg d...
The efficacy and tolerability of moclobemide (300-600 mg daily) and fluoxetine (20-40 mg daily) were...
Milnacipran is a new antidepressant with similar effects on the reuptake of noradrenaline and seroto...
OBJECTIVE: Some antidepressants, such as trazodone or clomipramine, can be administered intravenousl...
The analysis of three controlled studies comparing mianserin and clomipramine shows that none of the...
To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depre...
Contains fulltext : 29446.pdf (publisher's version ) (Open Access)In 16 depression...
A double-blind, randomized trial is described which was designed to compare the clinical effect of 1...
Objective: To review the efficacy and safety of moclobemide in comparison with TCAs (for our purpose...
The aim of this prospectively randomized, double-blind, parallel group, multicentre study was to com...
Moclobemide was compared with placebo for antidepressant activity, tolerance and safety in 2 paralle...
Moclobemide was compared to placebo in two parallel groups of depressed patients, in a multicenter r...
A dissertation submitted to Faculty of Medicine in part fulfilment of the required for the degree ...
An international, multicenter, placebo-controlled study was undertaken to determine the safety and a...
This paper reports the results of a multicentre study of the new monoamine oxidase inhibitor, moclob...
Thirty-two patients with primary depression completed treatment either with mianserin (30 to 60 mg d...
The efficacy and tolerability of moclobemide (300-600 mg daily) and fluoxetine (20-40 mg daily) were...
Milnacipran is a new antidepressant with similar effects on the reuptake of noradrenaline and seroto...
OBJECTIVE: Some antidepressants, such as trazodone or clomipramine, can be administered intravenousl...
The analysis of three controlled studies comparing mianserin and clomipramine shows that none of the...
To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depre...
Contains fulltext : 29446.pdf (publisher's version ) (Open Access)In 16 depression...
A double-blind, randomized trial is described which was designed to compare the clinical effect of 1...
Objective: To review the efficacy and safety of moclobemide in comparison with TCAs (for our purpose...
The aim of this prospectively randomized, double-blind, parallel group, multicentre study was to com...